Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Quality assurance of integrative big data for medical research within a multihospital system

(2022) Yi-Chia Lee et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of prophylactic high and low doses of corticosteroid on the efficacy of immune checkpoint blockade in murine hepatocellular carcinoma models.

(2022) Ying-Chun Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer

(2021) Mark N. Sorial et al.   EUROPEAN JOURNAL OF CANCER

Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors

(2021) Marcus Skribek et al.   EUROPEAN JOURNAL OF CANCER

Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions

(2021) Olivia M. Lansinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

(2021) Julie R Brahmer et al.   Journal for ImmunoTherapy of Cancer

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer

(2021) Diana V Maslov et al.   Journal for ImmunoTherapy of Cancer

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

(2021) Bryan J. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

(2020) Nasser H. Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

(2020) Ann-Lii Cheng et al.   JOURNAL OF HEPATOLOGY

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

(2020) Thomas Yau et al.   JAMA Oncology

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

(2020) David J Pinato et al.   Journal for ImmunoTherapy of Cancer

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

(2019) Biagio Ricciuti et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab

(2018) Susan Combs Scott et al.   Journal of Thoracic Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of pretreatment steroids on the development of immune related adverse events.

(2018) Philip Margiotta et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

(2018) Y -L Wu et al.   ANNALS OF ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids

(2015) Takumi Sakurada et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY